Biovest wins orphan drug status for cancer vax

Biovest International has announced that the FDA has granted orphan drug designation to BiovaxID, its personalized cancer vaccine, for a second lymphoma indication. "With promising clinical trials now complete in both follicular lymphoma and mantle cell lymphoma, we are preparing to seek regulatory approvals for BiovaxID in two separate indications," says Dr. Carlos Santos, Biovest's VP, product development & regulatory affairs. Release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.